You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新股速递 | 科济药业-B一手入场费16565.26港元,乙头门槛约662.61万港元,引入礼来、睿远、南方基金等9名基石
uSMART盈立智投 06-07 08:36

uSMART盈立智投6月7日消息,科济药业-B今日起招股,一手入场费16565.26港元,引入9名基石投资者,按上限定价计,合共锁定57.44%的发行股份。

科济药业-B是一家在中国及美国拥有业务的生物制药公司,专注于治疗血液恶性肿瘤和实体瘤的创新CAR-T细胞疗法。

招股信息

(1)简称及代码:科济药业-B,2171.HK

(2)招股日期:6月7日-10日

    公布中签日:6月17日

    上市日期:6月18日

    计息日:7天

(3)发售价:29.6港元-32.8港元

(4)入场费:每手500股,一手入场费16,565.26港元,乙头需申购20万股,金额约662.61万港元

(5)发行股数:94,747,000股(10%香港公开发售,90%国际发售)

(6)集资金额:28.05亿-31.08亿港元

(7)市值:167.93亿-186.09亿港元

(8)保荐人:高盛、瑞银

(9)基石投资者(9名):LAV(礼来) 、新华资本、CloudAlpha、睿远、WT、广发基金、Dymon Asia、常春藤、南方基金,按上限定价计,合共锁定57.44%的发行股份

(10)回拨机制:常规回拨

公开认购倍数为15倍或以上但少于50倍,公开发售比例从10%提升至30%

公开认购倍数为50倍或以上但少于100倍,公开发售比例从10%提升至40%

公开认购倍数为100倍或以上,公开发售比例从10%提升至50%

(11)中签率预测

目前打新市场情绪回温,最大比例回拨或是大概率事件,届时,公开发售股数为47,373,500股,共94747手,甲乙组分别约47373手,按25-45万人申购,一手中签率或为5%-10%。

点击可阅读《科济药业-B招股书》

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account